Monique A. Bertrand

Intact LKB1 activity is required for survival of dormant ovarian cancer spheroids

J. McGee, A. Sugimoto, E. Fazio, 2015, Oncotarget.

Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.

J. McGee, A. Sugimoto, E. Fazio, 2014, Carcinogenesis.

Cadherin switching in ovarian cancer progression

C. Maccalman, S. Getsios, Pavneesh Madan, 2003, International journal of cancer.

TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids.

J. McGee, A. Sugimoto, T. Shepherd, 2016, Endocrine-related cancer.

Added-value of SPECT/CT to lymphatic mapping and sentinel lymphadenectomy in gynaecological cancers.

L. Stitt, P. Zabel, I. Rachinsky, 2007, American journal of nuclear medicine and molecular imaging.

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer

M. Parmar, A. Oza, J. Ledermann, 2019, Gynecologic oncology.

Treatment Tolerance and Side Effects of Intraperitoneal Carboplatin and Dose-Dense Intravenous Paclitaxel in Ovarian Cancer.

J. McGee, S. Welch, A. Sugimoto, 2018, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Direct Genetics Referral Pathway for High-Grade Serous Ovarian Cancer Patients: The “Opt-Out” Process

N. Foley, J. McGee, S. Welch, 2019, Journal of oncology.

Intact LKB1 activity is required for survival of dormant ovarian cancer spheroids

A. Sugimoto, E. Fazio, T. Shepherd, 2015, Oncotarget.

Intact LKB1 activity is required for survival of dormant ovarian cancer spheroids

T. Shepherd, Yudith Ramos Valdés, T. Peart, 2015, Oncotarget.